M&A Deal Summary

Pharmion Acquires Cabrellis Pharmaceuticals

On November 16, 2006, Pharmion acquired life science company Cabrellis Pharmaceuticals for 59M USD

Acquisition Highlights
  • This is Pharmion’s 1st transaction in the Life Science sector.
  • This is Pharmion’s largest (disclosed) transaction.
  • This is Pharmion’s 1st transaction in the United States.
  • This is Pharmion’s 1st transaction in California.

M&A Deal Summary
Date 2006-11-16
Target Cabrellis Pharmaceuticals
Sector Life Science
Buyer(s) Pharmion
Deal Type Add-on Acquisition
Deal Value 59M USD

Target

Cabrellis Pharmaceuticals

San Diego, California, United States
Cabrellis Pharmaceuticals Corp. is a developer of third-generation synthetic anthracycline for small-cell lung cancer.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pharmion

Boulder, Colorado, United States
Category Company
Founded 1999
Sector Life Science
Employees166
DESCRIPTION

Pharmion Corporation is a global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza®, a DNA demethylating agent.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2006) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal